PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

44,990 stories, page 640 of 750

Advanced search
🌍discoverynews.google.comTier 3 · Aggregated media

GLP-1 and neurodegeneration: lessons from a failed trial

Drug Discovery NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Cold Chain Packaging Market to Reach $93.1 Billion by 2033 Amid Pharmaceutical and E-commerce Pressures

Healthcare PackagingOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

'Exciting' Clinical Trial Results For New Endometriosis Scan

Medical News BulletinOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Investing News NetworkOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Europe's CHMP reverses endorsement of Tavneos as Amgen FDA hearing looms

Fierce PharmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Definium releases LSD for depression Phase 3 results and Colorado activists fight recent bill’s amendments to sharing psychedelics

The MicrodoseOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Anivive Lifesciences Announces FDA Approval of Laverdia Oral Treatment for Canine Lymphoma

Pet AgeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA Makes Free Drinking Water Mandatory At Restaurants, Hotels & Eateries

lokmattimes.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

European Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologies

PharmTech.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

GEODIS Thermal Covers Mark Step Toward Sustainable Pharma Airfreight Packaging

Pharmaceutical CommerceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Fermenta Biotech Limited Ranked 7th Nationwide in India’s Great Mid-size WorkplacesTM 2026

Roastbrief USOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says

Fierce BiotechOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings

Barchart.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired

RTTNewsOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

UKHSA extends red heat-health alerts across England

The red heat-health alerts in place for the West Midlands, East Midlands, South East, South West, Lo...

UK Health Security AgencyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

What's Fueling Olema Pharmaceuticals' Explosive 242% Stock Surge

Kavout | AIOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Capricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel BLA in Duchenne Muscular Dystrophy on July 29, 2026

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout

Fierce BiotechOriginal source
🌍discoverynews.google.comTier 2 · Trade media

BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review

BioSpaceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A second report says 'elevated' abortions due to mail-order pills and 'shield laws'

liveaction.orgOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to book forward of Sunhawk Vision Biotech, Inc. – TPEX:7759

TradingViewOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Embryo editing advances reignite ethical debates

statnews.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Market Europe – June 2026

PMLiVEOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

What's Driving Rallybio's Recent Surge and Investor Interest

Kavout | AIOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

PR NewswireOriginal source
🌍discoverynews.google.comTier 2 · Trade media

The deal before the deal

Fierce BiotechOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A Dose of Disruption: Read the full investigative series on Empower

Houston ChronicleOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBITDA forward of RTW Biotech Opportunities Ltd USD – FWB:0BM

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

How China Turned US Trade Compliance Into a Supply Chain Risk

Pharmaceutical CommerceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of Grand Pharmaceutical Group Limited – HKEX:512

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Capricor to Present Positive Five-Year HOPE-2 OLE Data and

GlobeNewswireOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Capricor's Duchenne drug shows 5-year muscle and heart data at PPMD

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

“It’s time to Act”: EU biotech to undergo major changes

Labiotech.euOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells

Fierce BiotechOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Star Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlight

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress

Business WireOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Don’t Make AI Smarter. Make It Traceable.

PharmTech.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Lupin's FDA Nod Signals Shakeup for a $3.5B Prostate Cancer Drug Market

BriefGlanceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

markets.businessinsider.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra mandates calorie labels, free drinking water at restaurants under new food safety order

Storyboard18Original source
🇨🇦Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Remifentanil hydrochloride for injection; Out of specification (Assay & Impurity)

The assay and impurity is out of specification in the affected lots.

Health Canada Recalls and Safety AlertsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Ensysce starts final PF614-MPAR study stage for overdose-protection opioid

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotech

ChartMillOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Group files brief urging FDA's reinstatement of abortion pill restriction

liveaction.orgOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

OST-HER2 plus radiation lifts 2-year survival in dogs with bone cancer

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

IMCD opens US dietary supplements technical hub to accelerate innovation

Nutrition InsightOriginal source
🌍Industryinvestors.vivani.comTier 1 · Company source

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

Vivani MedicalOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Q&A: Why Pharma Deal Volume Is Down but Value Is Up

PharmTech.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBITDA forward of Purple Biotech Ltd. – NASDAQ:PPBT

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.

PluangOriginal source
🌍Researchpnas.orgTier 2 · Direct publisher

Prions can tune mutation rates to accelerate evolution and drive drug resistance

PNASOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Key takeaways from a Chronicle examination of Empower Pharmacy

Houston ChronicleOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Here's how we examined Houston-based Empower Pharmacy's expansion

Houston ChronicleOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Omakase World Market is the Bay Area's most surprising new food hall

SFGATEOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA to discuss easing restrictions on peptides despite safety concerns

The GuardianOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Rx Rundown: Merck KGaA, AbbVie, Sangamo Therapeutics and more

Medical Marketing and MediaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Weighs Legalizing Gray-Market Peptides Amid Escalating Safety Concerns

streamlinefeed.co.keOriginal source